Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075663 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL2690340 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL3075660 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL2690338 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL19915056 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL29102381 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL26143938 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL220833 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL622600 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL26363782 | 0.90 | CHRM2 (0.46) | CHRM2CHRM1CHRM3PREPRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062007-B2 | Cyclic amide BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | Merck, Sharp & Dohme Corp. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278334-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | Merck, Sharp & Dohme Corp. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8168657-B2 | administering a solenopsin derivative such as 2-methyl-6-(2-phenylethyl)piperidine or other piperidine derivatives to treat a tumor or cancer in a patient | BOWEN J PHILLIP (US) | 2012-05-01 | — | — | US | disclosed |
| US-7790753-B2 | Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-09-07 | — | — | US | disclosed |
| US-20100152138-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP. | 2010-06-17 | — | — | US | disclosed |
| US-7662816-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | SCHERING CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1660443-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | BOWEN J PHILLIP (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1472223-A1 | GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-20040048848-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2003066592-A1 | GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003061598-A2 | SOLENOPSIN A, B AND ANALOGS AS NOVEL ANGIOGENESIS INHIBITORS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1138679-B1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEM RES (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-6392059-B1 | THERAPY FOR ALZHEIMER'S DISEASE | SAGAMI CHEMICAL REASEARCH CENTER (JP) | 2002-05-21 | — | — | US | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
| EP-1138679-A1 | HYDRONAPHTHO 2,3-c]FURAN DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | CHRM2 429/4885CHRM1 428/4885CHRM3 802/4885 |
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | CHRM2 1541/4885CHRM1 1139/4885CHRM3 840/4885 |
| US-20100152138-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | CHRM2 261/4885CHRM1 209/4885CHRM3 491/4885 |
| US-20040048848-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, PSEN1 | CHRM2 2167/4885CHRM1 1860/4885CHRM3 1194/4885 |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | CHRM2 261/4885CHRM1 209/4885CHRM3 491/4885 |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | VEGFA, TEK, FLT1 | CHRM2 4884/4885CHRM1 4872/4885CHRM3 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.